Clinical Trial

Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients

Study acronym: CEMI-first
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is an open-label, singel arm, prospective, multicenter phase II trial evaluating the efficacy and safety of Cemiplimab when applied as first-line therapy in patients with locally advanced basal cell carcinoma (BCC), which were not pretreated with hedgehog inhibitors (HHI).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-05-12; most recent amendment 2026-03-10.
Status change: Not Yet Recruiting → Recruiting 2025-08-14
Trial Details
NCT Number NCT06981325
Lead Sponsor Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators: Skin Cancer Center Minden, Department of Dermatology, Johannes-Wesling-Klinikum Minden, Universität Duisburg-Essen, Regeneron Pharmaceuticals
Conditions Basal Cell Carcinoma (BCC), First Line Treatment
Enrollment 34 participants
Start Date 2025-08-07
Primary Completion 2028-10 (estimated)
Study Completion 2029-07 (estimated)
Updated on ClinicalTrials.gov 2026-03-11